{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:10:45Z","timestamp":1791508245307,"version":"4.3.4"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:00:00Z","timestamp":1614470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 CA201594"],"award-info":[{"award-number":["K23 CA201594"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA762292"],"award-info":[{"award-number":["P30 CA762292"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R25 CA090314"],"award-info":[{"award-number":["R25 CA090314"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor T\u2010cell therapy with axicabtagene ciloleucel (axi\u2010cel) has considerably improved survival in adults with relapsed\/refractory large B\u2010cell lymphoma. This study reports patient\u2010reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90\u00a0days after treatment. Hematologic cancer patients treated with axi\u2010cel (<jats:italic>N<\/jats:italic>\u00a0=\u00a0103, mean age\u00a0=\u00a061, 39% female) completed SF\u201036 or PROMIS\u201029 QOL questionnaires prior to treatment and 90\u00a0days after. PRO\u2010Common Terminology Criteria for Adverse Events toxicity items were completed by patients at baseline and 14, 30, 60, and 90\u00a0days after treatment. Mixed models examined change in PROs over time. From preinfusion to 90\u00a0days later, patients reported improvements in physical functioning, pain, and fatigue (<jats:italic>p<\/jats:italic>s\u00a0&lt;\u00a00.01), but worsening of anxiety (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.02). Patient\u2010reported toxicities worsened by day 14 with improvement thereafter. The five most severe symptoms at day 14 included fatigue, decreased appetite, dry mouth, diarrhea frequency, and problems with concentration. Results indicate improvement in some domains of QOL over time with transient patient\u2010reported toxicities.<\/jats:p>","DOI":"10.1002\/cam4.3664","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T09:25:01Z","timestamp":1614504301000},"page":"1936-1943","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Acute patient\u2010reported outcomes in B\u2010cell malignancies treated with axicabtagene ciloleucel"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-8132","authenticated-orcid":false,"given":"Aasha I.","family":"Hoogland","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center Department of Health Outcomes and Behavior Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena V.","family":"Jayani","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center Department of Medicine Division of Hematology\/Oncology Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Collier","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Health Outcomes and Behavior Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaly","family":"Irizarry\u2010Arroyo","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Health Outcomes and Behavior Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvelise","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Health Outcomes and Behavior Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Booth\u2010Jones","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Supportive Care Medicine Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-5306","authenticated-orcid":false,"given":"Kelly A.","family":"Hyland","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Health Outcomes and Behavior Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"James","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Health Outcomes and Behavior Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Barata","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Health Outcomes and Behavior Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Bachmeier","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Malignant Hematology Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Khimani","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel S.","family":"Krivenko","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien D.","family":"Liu","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla\u2010Ibarz","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Malignant Hematology Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Malignant Hematology Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneer","family":"Abidi","sequence":"additional","affiliation":[{"name":"Spectrum Health Cancer Center Michigan State University Grand Rapids MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather S. L.","family":"Jim","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Department of Health Outcomes and Behavior Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_9_8_1","volume-title":"Axicabtagene Ciloleucel (axicel) CD19 Chimeric Antigen Receptor (CAR) T\u2010Cell Therapy for Relapsed\/Refractory Large B\u2010Cell Lymphoma: Real World Experience","author":"Nastoupil LJ","year":"2018"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2035"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.222"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.11.025"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr485"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2923-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29717"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.025"},{"issue":"8","key":"e_1_2_9_16_1","first-page":"530","article-title":"Agreement between patient\u2010reported symptoms and their documentation in the medical record","volume":"14","author":"Pakhomov SV","year":"2008","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2016.0656"},{"key":"e_1_2_9_18_1","volume-title":"Proposed National Coverage Determination for Chimeric Antigen Receptor (CAR) T\u2010cell Therapy","author":"Jensen TS","year":"2019"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30097-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.037"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001026"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30493-0"},{"key":"e_1_2_9_23_1","volume-title":"SF\u201036 Health Survey: Manual and Interpretation Guide","author":"Ware JE","year":"1993"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-1842-3"},{"key":"e_1_2_9_25_1","volume-title":"National Coverage Determination for Chimeric Antigen Receptor (CAR) T\u2010cell Therapy for Cancers","author":"Jensen TS","year":"2019"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1179-0"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.11.014"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31089"},{"key":"e_1_2_9_30_1","volume-title":"PROsetta Stone \u00ae Methodology: A Rosetta Stone for Patient Reported Outcomes","author":"Choi SW"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0035768"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2639"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.08.012"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29877"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0420-6"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.08.006"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:20:00Z","timestamp":1693563600000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,28]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1002\/cam4.3664"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3664","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,28]]},"assertion":[{"value":"2020-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}